{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T17:49:26Z","timestamp":1777312166890,"version":"3.51.4"},"reference-count":32,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2012,6,1]],"date-time":"2012-06-01T00:00:00Z","timestamp":1338508800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["International Journal of Cardiology"],"published-print":{"date-parts":[[2012,6]]},"DOI":"10.1016\/j.ijcard.2012.03.051","type":"journal-article","created":{"date-parts":[[2012,3,28]],"date-time":"2012-03-28T06:06:15Z","timestamp":1332914775000},"page":"101-102","source":"Crossref","is-referenced-by-count":5,"title":["An evidence-based hypothesis for beneficial effects of telmisartan on Marfan syndrome"],"prefix":"10.1016","volume":"158","author":[{"given":"Hisato","family":"Takagi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirotaka","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kotaro","family":"Iwata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shin-nosuke","family":"Goto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuya","family":"Umemoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijcard.2012.03.051_bb0005","first-page":"41","article-title":"Telmisartan has the strongest binding affinity to angiotensin II type 1 receptor: comparison with other angiotensin II type 1 receptor blockers","volume":"25","author":"Kakuta","year":"2005","journal-title":"Int J Clin Pharmacol Res"},{"key":"10.1016\/j.ijcard.2012.03.051_bb0010","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1161\/01.HYP.0000123072.34629.57","article-title":"Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity","volume":"43","author":"Benson","year":"2004","journal-title":"Hypertension"},{"key":"10.1016\/j.ijcard.2012.03.051_bb0015","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1126\/science.1124287","article-title":"Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome","volume":"312","author":"Habashi","year":"2006","journal-title":"Science"},{"key":"10.1016\/j.ijcard.2012.03.051_bb0020","doi-asserted-by":"crossref","first-page":"2802","DOI":"10.1161\/CIRCULATIONAHA.107.693523","article-title":"Medical management of Marfan syndrome","volume":"117","author":"Keane","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2012.03.051_bb0025","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1056\/NEJMoa055695","article-title":"Aneurysm syndromes caused by mutations in the TGF-beta receptor","volume":"355","author":"Loeys","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijcard.2012.03.051_bb0030","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1083\/jcb.200608167","article-title":"Fibrillin-1 regulates the bioavailability of TGFbeta1","volume":"176","author":"Chaudhry","year":"2007","journal-title":"J Cell Biol"},{"key":"10.1016\/j.ijcard.2012.03.051_bb0035","doi-asserted-by":"crossref","first-page":"2750","DOI":"10.1074\/jbc.M209256200","article-title":"Latent transforming growth factor beta-binding protein 1 interacts with fibrillin and is a microfibril-associated protein","volume":"278","author":"Isogai","year":"2003","journal-title":"J Biol Chem"},{"key":"10.1016\/j.ijcard.2012.03.051_bb0040","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/ng1116","article-title":"Dysregulation of TGF-beta activation contributes to pathogenesis in Marfan syndrome","volume":"33","author":"Neptune","year":"2003","journal-title":"Nat Genet"},{"key":"10.1016\/j.ijcard.2012.03.051_bb0045","doi-asserted-by":"crossref","unstructured":"Ng CM, Cheng A, Myers LA, et al. TGF-beta-dependent pathogenesis of mitral valve prolapse in a mouse model of Marfan syndrome. J Clin Invest 2004;114:1586\u201392.","DOI":"10.1172\/JCI200422715"},{"issue":"6 Suppl","key":"10.1016\/j.ijcard.2012.03.051_bb0050","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.ahj.2009.04.005","article-title":"Evolving understanding of the renin\u2013angiotensin\u2013aldosterone system: pathophysiology and targets for therapeutic intervention","volume":"157","author":"Gradman","year":"2009","journal-title":"Am Heart J"},{"key":"10.1016\/j.ijcard.2012.03.051_bb0055","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.mce.2008.11.007","article-title":"Mechanisms and functions of agonist-independent activation in the angiotensin II type 1 receptor","volume":"302","author":"Akazawa","year":"2009","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/j.ijcard.2012.03.051_bb0060","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/ncb1137","article-title":"Mechanical stress activates angiotensin II type 1 receptor without the involvement of angiotensin II","volume":"6","author":"Zou","year":"2004","journal-title":"Nat Cell Biol"},{"key":"10.1016\/j.ijcard.2012.03.051_bb0065","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1161\/01.CIR.103.6.789","article-title":"Angiotensin II blockade reverses myocardial fibrosis in a transgenic mouse model of human hypertrophic cardiomyopathy","volume":"103","author":"Lim","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2012.03.051_bb0070","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1097\/01.hjh.0000182521.44440.c5","article-title":"Neutralization of transforming growth factor-beta attenuates hypertension and prevents renal injury in uremic rats","volume":"23","author":"Lavoie","year":"2005","journal-title":"J Hypertens"},{"key":"10.1016\/j.ijcard.2012.03.051_bb0075","doi-asserted-by":"crossref","first-page":"F278","DOI":"10.1152\/ajprenal.00139.2003","article-title":"Angiotensin II induces thrombospondin-1 production in human mesangial cells via p38 MAPK and JNK: a mechanism for activation of latent TGF-beta1","volume":"286","author":"Naito","year":"2004","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.ijcard.2012.03.051_bb0080","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1111\/j.1365-2362.2009.02183.x","article-title":"Effects of AT1- and beta-adrenergic receptor antagonists on TGF-beta1-induced fibrosis in transgenic mice","volume":"39","author":"Seeland","year":"2009","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.ijcard.2012.03.051_bb0085","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1002\/msj.20200","article-title":"Drug-based therapies for vascular disease in Marfan syndrome: from mouse models to human patients","volume":"77","author":"Cook","year":"2010","journal-title":"Mt Sinai J Med"},{"key":"10.1016\/j.ijcard.2012.03.051_bb0090","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.ahj.2007.06.024","article-title":"Rationale and design of a randomized clinical trial of beta-blocker therapy (atenolol) versus angiotensin II receptor blocker therapy (losartan) in individuals with Marfan syndrome","volume":"154","author":"Lacro","year":"2007","journal-title":"Am Heart J"},{"key":"10.1016\/j.ijcard.2012.03.051_bb0095","doi-asserted-by":"crossref","first-page":"354","DOI":"10.2459\/JCM.0b013e3283232a45","article-title":"Rationale and design of a trial evaluating the effects of losartan vs. nebivolol vs. the association of both on the progression of aortic root dilation in Marfan syndrome with FBN1 gene mutations","volume":"10","author":"Gambarin","year":"2009","journal-title":"J Cardiovasc Med (Hagerstown)"},{"key":"10.1016\/j.ijcard.2012.03.051_bb0100","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1745-6215-11-3","article-title":"Losartan therapy in adults with Marfan syndrome: study protocol of the multi-center randomized controlled COMPARE trial","volume":"11","author":"Radonic","year":"2010","journal-title":"Trials"},{"key":"10.1016\/j.ijcard.2012.03.051_bb0105","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.acvd.2010.04.008","article-title":"Rationale and design of a randomized clinical trial (Marfan Sartan) of angiotensin II receptor blocker therapy versus placebo in individuals with Marfan syndrome","volume":"103","author":"Detaint","year":"2010","journal-title":"Arch Cardiovasc Dis"},{"key":"10.1016\/j.ijcard.2012.03.051_bb0110","article-title":"The Ghent Marfan Trial \u2014 a randomized, double-blind placebo controlled trial with losartan in Marfan patients treated with \u03b2-blockers","author":"M\u00f6berg","year":"2011","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.ijcard.2012.03.051_bb0115","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1046\/j.1523-1755.2001.0590051899.x","article-title":"Peroxisome proliferator-activated receptor-gamma agonist troglitazone protects against nondiabetic glomerulosclerosis in rats","volume":"59","author":"Ma","year":"2001","journal-title":"Kidney Int"},{"key":"10.1016\/j.ijcard.2012.03.051_bb0120","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1536\/ihj.48.637","article-title":"Combination therapy with telmisartan and spironolactone alleviates L-NAME exacerbated nephrosclerosis with an increase in PPAR-gamma and decrease in TGF-beta(1)","volume":"48","author":"Takahashi","year":"2007","journal-title":"Int Heart J"},{"key":"10.1016\/j.ijcard.2012.03.051_bb0125","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1007\/s11596-008-0512-z","article-title":"Telmisartan but not valsartan inhibits TGF-beta-mediated accumulation of extracellular matrix via activation of PPARgamma","volume":"28","author":"Yao","year":"2008","journal-title":"J Huazhong Univ Sci Technolog Med Sci"},{"key":"10.1016\/j.ijcard.2012.03.051_bb0130","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/aps.2009.174","article-title":"PPARgamma agonists inhibit TGF-beta-PKA signaling in glomerulosclerosis","volume":"31","author":"Zou","year":"2010","journal-title":"Acta Pharmacol Sin"},{"key":"10.1016\/j.ijcard.2012.03.051_bb0135","doi-asserted-by":"crossref","first-page":"575","DOI":"10.3109\/10715762.2011.560149","article-title":"Telmisartan attenuates oxidative stress and renal fibrosis in streptozotocin induced diabetic mice with the alteration of angiotensin-(1\u20137) mas receptor expression associated with its PPAR-\u03b3 agonist action","volume":"45","author":"Lakshmanan","year":"2011","journal-title":"Free Radic Res"},{"key":"10.1016\/j.ijcard.2012.03.051_bb0140","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1038\/labinvest.2011.45","article-title":"Telmisartan, a unique ARB, improves left ventricular remodeling of infarcted heart by activating PPAR gamma","volume":"91","author":"Maejima","year":"2011","journal-title":"Lab Invest"},{"key":"10.1016\/j.ijcard.2012.03.051_bb0145","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1161\/01.HYP.23.5.587","article-title":"Angiotensin receptor regulates cardiac hypertrophy and transforming growth factor-beta 1 expression","volume":"23","author":"Everett","year":"1994","journal-title":"Hypertension"},{"key":"10.1016\/j.ijcard.2012.03.051_bb0150","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1007\/s001099900028","article-title":"Angiotensin II stimulates expression of transforming growth factor beta receptor type II in cultured mouse proximal tubular cells","volume":"77","author":"Wolf","year":"1999","journal-title":"J Mol Med (Berl)"},{"key":"10.1016\/j.ijcard.2012.03.051_bb0155","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S0895-7061(99)00152-1","article-title":"Angiotensin II upregulates transforming growth factor-beta type I receptor on rat vascular smooth muscle cells","volume":"13","author":"Fukuda","year":"2000","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.ijcard.2012.03.051_bb0160","doi-asserted-by":"crossref","first-page":"239-40","DOI":"10.1016\/j.ijcard.2011.10.119","article-title":"Ethics in the authorship and publishing of scientific articles","volume":"153","author":"Coats","year":"2011","journal-title":"Int J Cardio"}],"container-title":["International Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527312002562?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527312002562?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,6,26]],"date-time":"2019-06-26T05:06:15Z","timestamp":1561525575000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167527312002562"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,6]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,6]]}},"alternative-id":["S0167527312002562"],"URL":"https:\/\/doi.org\/10.1016\/j.ijcard.2012.03.051","relation":{},"ISSN":["0167-5273"],"issn-type":[{"value":"0167-5273","type":"print"}],"subject":[],"published":{"date-parts":[[2012,6]]}}}